Abstract
Vascular damage in systemic lupus erythematosus (SLE) occurs through vasculitis, premature atherosclerosis, and hypercoagulability (predominantly due to the antiphospholipid antibody syndrome). In the Hopkins Lupus Cohort, a prospective cohort study, the incidence of thrombosis is 2 per 100 person-years of follow-up. Markers of immune-complex mediated injury (high anti-dsDNA and low C3), atherosclerosis (hypertension, hyperlipidemia, homocysteine) and antiphospholipid antibodies (lupus anticoagulant or anticardiolipin) are independent predictors of thrombosis. Hydroxychloroquine use is protective against future thrombosis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 191-193 |
| Number of pages | 3 |
| Journal | Scandinavian Journal of Rheumatology |
| Volume | 25 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1996 |
Keywords
- Anticardiolipin
- Antiphospholipid antibodies
- Lupus anticoagulant
- Thrombosis
ASJC Scopus subject areas
- Immunology and Allergy
- Rheumatology
- Immunology